Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
PYX-106 · 1 trial · 1 indication
Type, incidence, seriousness and causality of AEs based on National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE) Version 5.0. Any clinically significant changes in clinical laboratory parameters, vital signs, and electrocardiogram (ECG) parameters will be recorded as AEs.
| Arm | Type | Description |
|---|---|---|
| PYX-106 Dose Escalation | EXPERIMENTAL | Participants will receive escalating doses of PYX-106 to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary anti-tumor activity of PYX-106, and to determine the recommended dose(s). |
| Name | Type | Description |
|---|---|---|
| PYX-106 | DRUG | Intravenous (IV) infusion |
Inclusion Criteria: 1. Participants with histologically or cytologically confirmed solid tumors who have relapsed, been non-responsive, or have developed disease progression through standard therapy. 2. Histologically or cytologically confirmed solid tumors (see details below): For the dose esc...
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Merck & Co., Inc. | MRK | 2 | PHASE2 | pembrolizumab |
| Incyte Corporation | INCY | 1 | PHASE2 | Chemotherapy, Retifanlimab |
| Iovance Biotherapeutics Inc | IOVA | 2 | PHASE2 | E7 TCR-T cells, Aldesleukin |
| Novartis AG Sponsored ADR | NVS | 1 | PHASE1 | KFA115, pembrolizumab |
| AstraZeneca PLC | AZN | 1 | - | Trastuzumab deruxtecan |
PYX-106 is an investigational small molecule being developed for the treatment of solid tumors. It is currently in Phase 1 clinical development, with an active clinical trial studying its effects in patients with solid tumors. The drug is not yet approved and remains under investigation.
PYX-106 targets Siglec-15, a protein involved in the regulation of immune responses. By targeting Siglec-15, PYX-106 may modulate the tumor microenvironment to potentially enhance anti-tumor immunity. This mechanism is being evaluated in early-phase clinical trials for solid tumors.
PYX-106 is being developed by Pyxis Oncology, Inc., a biopharmaceutical company. The company is conducting a Phase 1 clinical trial to evaluate the safety and efficacy of PYX-106 in patients with solid tumors. Pyxis Oncology is publicly traded under the ticker symbol PYXS.
PYX-106 is in Phase 1 clinical development. It is an investigational drug, meaning it has not been approved by regulatory authorities. The ongoing Phase 1 trial is actively enrolling or has completed enrollment, with a total of 47 participants planned, and is being conducted in the United States, Belgium, and Spain.
PYX-106 is being studied in a Phase 1 clinical trial with the identifier NCT05718557, titled 'Study of PYX-106 in Solid Tumors.' This trial is active but not recruiting, with an enrollment of 47 participants. It is an open-label, uncontrolled study involving adult patients with solid tumors.
PYX-106 is the primary name for this investigational drug. No alternative names have been reported for PYX-106. It is a distinct small molecule targeting Siglec-15, currently in Phase 1 development for solid tumors by Pyxis Oncology.